We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

New Scanning Method Combines Two MRI Techniques to Detect Deadly Heart Condition Before Symptoms Appear

By MedImaging International staff writers
Posted on 20 Jul 2023
Print article
Image: New scanning methods can detect deadly hypertrophic cardiomyopathy ahead of symptoms (Photo courtesy of UCL)
Image: New scanning methods can detect deadly hypertrophic cardiomyopathy ahead of symptoms (Photo courtesy of UCL)

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by thicker than normal heart muscle walls, affecting the heart's ability to pump blood efficiently. HCM is a primary cause of heart failure and sudden cardiac death. A new study has revealed that a combination of two types of heart scan techniques could enable medical professionals to detect HCM earlier than current conventional tests allow. This early detection of HCM could also support trials exploring gene therapies and medications aimed at preventing the disease's development in high-risk individuals.

In collaborative research involving investigators from University College London (UCL, London, UK), the team analyzed the hearts of three groups: healthy individuals, patients already diagnosed with HCM, and people with an HCM-inducing genetic mutation but no observable signs of the disease (no heart muscle thickening). The team employed two advanced heart scanning techniques: cardiac diffusion tensor imaging (cDTI), a type of MRI scan that reveals how individual heart muscle cells are organized and packed together (the heart's microstructure), and cardiac MRI perfusion (perfusion CMR), which identifies problems with small blood vessels supplying the heart muscle (microvascular disease).

The scans revealed that individuals with overt HCM symptoms exhibit severely disorganized heart muscle cells and a high incidence and severity of microvascular disease compared to healthy participants. Importantly, the scans were also capable of detecting abnormal microstructure (muscle cell disorganization) and microvascular disease in those carrying the problematic gene yet without any symptoms or muscle thickening. The researchers found that 28% of these individuals had blood supply defects compared to healthy volunteers. This enabled doctors to more accurately identify early HCM signs developing in patients' hearts.

Mavacamten - the first medication to slow HCM progression - recently received approval in Europe, allowing doctors to mitigate the disease's severity once symptoms and muscle thickening become apparent. In addition, genetic therapies are being developed that could potentially prevent symptoms altogether by intercepting HCM at an early stage. Perfusion CMR is already employed in some clinics to distinguish HCM patients from other causes of muscle thickening. The researchers believe that these groundbreaking therapies, combined with cDTI and perfusion CMR scans, offer doctors the best opportunity yet to treat high-risk HCM individuals early enough to prevent the disease's development.

“The ability to detect early signs of HCM could be crucial in trials testing treatments aimed at preventing early disease from progressing or correcting genetic mutations. The scans could also enable treatment to start earlier than we previously thought possible,” said Dr. George Joy from the UCL Institute of Cardiovascular Science who led the research. “We now want to see if we can use the scans to identify which patients without symptoms or heart muscle thickening are most at risk of developing severe HCM and its life-changing complications. The information provided from scans could therefore help doctors make better decisions on how best to care for each patient.”

Related Links:

Gold Member
Solid State Kv/Dose Multi-Sensor
Remote Controlled Digital Radiography and Fluoroscopy System
Eco Track-DRF - MARS 50/MARS50+/MARS 65/MARS 80
Trimline Basic
Ultrasound System

Print article



view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

General/Advanced Imaging

view channel
Image: The NeuroLF ultra-compact brain Positron Emission Tomography (PET) scanner (Photo courtesy of Positrigo)

Breakthrough Brain PET System Aids Diagnosis of Neurological Disorders

Alzheimer's disease (AD) is the most prevalent type of dementia, representing approximately 70% of all dementia cases in individuals over 60 years of age. As of 2020, there were more than 55 million people... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Calantic Digital Solutions is an orchestrated suite of AI radiology solutions that aims to transform radiology (Photo courtesy of Bayer)

Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions

Imaging data constitutes approximately 90% of all medical data, with the volume of such data continuously expanding, thereby significantly increasing the workload for radiologists amid existing resource limitations.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.